Remimazolam for Cataract Surgery

Sponsor
University of California, Los Angeles (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05980117
Collaborator
(none)
120
1
2
8
15

Study Details

Study Description

Brief Summary

The goal of this study is to assess any post operative cognitive changes following benzodiazepine administration during cataract surgery. The investigators will compare effects of Midazolam vs. Remimazolam on cognition at the time of discharge from the post operative care unit and the next day following surgery.

Cognitive changes will be assessed by administration of Montreal Cognitive Assessment (MoCA).

Participants will:
  1. Complete MoCA testing prior to surgery

  2. Randomize in either Midazolam or study drug Remimazolam

  3. Complete MoCA testing after surgery at the time of discharge in the post anesthesia care unit and the next day of surgery at the time of post operative surgical visit.

  4. Complete Patient Satisfaction Survey at the time of discharge from the Post Anesthesia Care Unit (PACU)

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

Cataract surgery (clouded natural lens of eye removed and clear artificial lens implanted) is the most common eye surgery performed in elderly patients. Although cataract surgery is a minor surgery, many patients are anxious and therefore benzodiazepine such as midazolam is administered during surgery to allay a patient's anxiety.

The purpose of this study is to look at any difference in postoperative cognitive changes as well as recovery times in the PACU following administration of midazolam or remimazolam.

Patients will be asked to participate in a clinical trial where they will be randomly assigned to midazolam or remimazolam group. Cognitive changes will be assessed by administration of MoCA test. MoCA test is a validated, objective short (about 10-15 minutes) screening tool for detection of mild neurocognitive dysfunction. Given the short half life of remimazolam, investigators hypothesize that any cognitive changes will be less with remimazolam compared to midazolam.

Patients will be asked to complete MoCA prior to surgery, in the recovery room following surgery, and the next day during their post-operative clinic visit. In addition, patients will be asked to rate their satisfaction of their anesthetic during their surgery.

The participant will be in this research study from the day of surgery until the first post-operative visit, the following day.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Patients will be randomized to the intervention group receiving Remimazolam or to the control group receiving Midazolam.Patients will be randomized to the intervention group receiving Remimazolam or to the control group receiving Midazolam.
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Comparison of Remimazolam vs. Midazolam for Sedation During Cataract Surgery
Anticipated Study Start Date :
Sep 1, 2023
Anticipated Primary Completion Date :
Feb 1, 2024
Anticipated Study Completion Date :
May 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention

Patients assigned to the study group will receive Remimazolam.

Drug: Remimazolam
Remimazolam (1.0mg IV) titrated to modified observer's assessment of sedation score of 3 -4 during cataract surgery.
Other Names:
  • Byfavo
  • Active Comparator: Control

    Patients assigned to the control group will receive Midazolam.

    Drug: Midazolam
    Midazolam (0.5-2mg IV) titrated to modified observer's assessment of sedation score of 3 - 4 during cataract surgery.
    Other Names:
  • Versed
  • Outcome Measures

    Primary Outcome Measures

    1. Change in MoCA score following surgery in the PACU and post operative day 1. [Immediately following surgery in the PACU and post operative day 1.]

      Montreal Cognitive Assessment (MoCA) test

    2. Change in MoCA Scores in PACU and the next day between midazolam and remimazolam group. [Immediately following surgery in the PACU, and post operative day 1.]

      Montreal Cognitive Assessment (MoCA) test

    3. Length of postoperative stay [Postop day 0 (day of surgery) until discharge from the hospital, usually on postop day 1 (an average of 1 day).]

      Duration from the time of admission to readiness for discharge from the PACU.

    Secondary Outcome Measures

    1. Surgeon Satisfaction [Intraoperatively to postoperatively in the ICU, and expected average of 1 hour.]

      Surgeon satisfaction score will be assessed post-surgery as measured by a 5-point scale with 1 = Strongly Disagree , 2 = Disagree , 3 = Neither Agree nor Disagree, 4 = Agree, 5 = Strongly Agree.

    2. Patient Satisfaction [Day of surgery]

      Patient satisfaction score will be assessed at the time of discharge by a 5 point scale with 1 = Disagree Strongly , 2 = Disagree Somewhat , 3 = Neither Agree or Disagree, 4 = Agree Somewhat, 5 = Agree Strongly.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    65 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Adult patients age > 65 years undergoing first eye cataract surgery under local topical anesthesia at the University of California, Los Angeles (UCLA).

    2. Both male and female patients

    3. American Society of Anesthesiologists Class 2, 3, and 4.

    Exclusion Criteria:
    1. Patients who are unable to consent for the study

    2. Patients who are unable to cooperate with the cognitive assessment such as patients with significant visual, auditory, language or other impairment.

    3. Patients who are unable to understand simple English commands.

    4. Patients who do not wish to have benzodiazepine medication during surgery

    5. Patients with a history of severe hypersensitivity reaction to dextran 40 or products containing dextran 40.

    6. Patients with chronic pain on opiates.

    7. Patients with a history of drug, alcohol abuse/dependence.

    8. Patients with BMI > 40.

    9. Patients with obstructive sleep apnea (moderate to severe).

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Ronald Reagan UCLA Medical Center, Department of Anesthesiology & Perioperative Medicine Los Angeles California United States 90095

    Sponsors and Collaborators

    • University of California, Los Angeles

    Investigators

    • Principal Investigator: Zhuang Fang, MD, University of California, Los Angeles

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Zhuang T. Fang, MD, Principal Investigator, University of California, Los Angeles
    ClinicalTrials.gov Identifier:
    NCT05980117
    Other Study ID Numbers:
    • 22-001570
    First Posted:
    Aug 7, 2023
    Last Update Posted:
    Aug 7, 2023
    Last Verified:
    Aug 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    Yes
    Keywords provided by Zhuang T. Fang, MD, Principal Investigator, University of California, Los Angeles
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 7, 2023